Articles tagged with Hepatitis B
Research reveals that commonly used antiretroviral drugs TAF and TDF directly impact mitochondria's energy production in immune cells. The study suggests a larger energy reduction when combined with other antiretrovirals, sparking concerns about potential long-term effects on human cells.
A study published in Journal of Hepatology found that efficient priming of HBV-specific CD4 T cells is crucial for the success of therapeutic hepatitis B vaccination. The researchers developed a novel heterologous prime-boost vaccine, TherVacB, which induced antiviral efficacy in preclinical mouse models.
African patients with chronic hepatitis B face limited access to treatment due to inadequate guidelines. Researchers propose lower treatment thresholds and better adapted guidelines for the African population.
Researchers used WGS data of 10,585 people from China to construct the first blood virological profile of the Chinese population. The study identified 14 viruses widely present in the population, including hepatitis B virus, which was detected in 1.69% of individuals.
A UNIGE team identified a three-step mechanism that allows our body to defend itself against hepatitis B. The complex detects the viral DNA, traps it, and inhibits the virus' chromosome.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.
The National Institutes of Health has updated its Strategic Plan to Cure Hepatitis B, focusing on developing a cure and improving vaccination, screening, and follow-up care strategies. The revised plan aligns with the Department of Health and Human Services' Viral Hepatitis National Strategic Plan.
The new grant aims to address structural racism and discrimination affecting Asian-Americans with chronic hepatitis B virus infection and liver cancer. Researchers will examine factors such as socio-historical hardship, segregation, and mistrust of the health system to improve quality of care.
Researchers discuss Hepatitis D's life cycle and interactions with its host, exploring strategies for further research to combat this overlooked virus. HDV coinfects people with hepatitis B, rapidly progressing to liver cirrhosis and cancer if left untreated, with a review published in the Chinese Medical Journal.
A University of Waterloo study found that current Hepatitis B vaccination, screening, and treatment strategies in Ontario would leave the province short of its goal to reduce preventable infections. The report's authors developed a computer model simulating long-term effects of existing strategies, which they found would only decrease ...
A new grant will help Missouri parents make informed decisions about vaccinating their children against various diseases. The grant aims to provide factual, evidence-based information to address common concerns and promote public health outcomes.
Researchers have made a breakthrough in enhancing the antiviral T cell response triggered by therapeutic vaccines for chronic hepatitis B. By removing natural killer cells and activating them with cytokines, they boosted the control of HBV infection.
The new schedule includes revised guidance on the hepatitis B vaccine for adults aged 60 years and older, as well as simplified recommendations for pneumococcal vaccinations. The updated schedule also recommends co-administration of COVID-19 vaccines with other vaccines.
Immunosequencing of T cells combined with machine learning techniques reveals that participants with higher numbers of pre-existing memory CD4 T cells develop immunity more quickly and produce more antibodies following vaccination. This study has significant implications for immunity and vaccine development efforts.
Research found that patients with hepatitis B were unable to afford generic drug entecavir due to high out-of-pocket costs, despite generic manufacturer competition. The study concludes that patients appear shielded from benefits of generic competition, leading to a significant patient-cost burden.
A new study reveals hepatitis B virus (HBV) has been infecting humans for millennia, tracing its evolution from prehistory to the present. The research highlights HBV's dispersal routes and shifts in viral diversity mirroring human migrations and demographic events.
Researchers successfully simulated the capsid disassembly step of hepatitis B viral infection at an unprecedented atomic level, identifying specific regions of the capsid protein that contribute to breakage. This high-accuracy simulation can help design drugs to interrupt these processes and prevent chronic infection.
Scientists have developed stable peptide mimics called peptoids to treat viruses and prevent infections. Peptoids, such as those tested against SARS-CoV-2 and HSV-1, could one day cure or prevent many kinds of infections, including COVID-19.
A new biomarker, HBcrAg, has been found to accurately predict viral load in patients with chronic hepatitis B and reflect response to anti-viral treatments. This discovery may lead to improved monitoring methods for CHB, enabling clinical decisions and potentially improving patient outcomes.
Researchers identified a new hepatitis B virus in donkeys and zebras that causes prolonged infections, potentially leading to better understanding of chronic hepatitis B and development of new therapies.
Researchers have developed a combination therapy that can potentially heal hepatitis B by shutting down the viral genome in infected liver cells. The treatment targets the HBx protein, which protects the genetic material from being silenced, allowing for sustained shutdown of the virus.
The USPSTF recommends screening for hepatitis B virus infection in adolescents and adults at increased risk due to its effectiveness in reducing mortality and hepatocellular carcinoma. Antiviral therapy improves intermediate outcomes associated with better health outcomes, strengthening the 2014 recommendation.
A West Virginia University study suggests that local health departments are crucial in getting the hepatitis B vaccine to those who need it most, particularly individuals at risk of contracting the virus. The study found that partnerships between health departments and local drug treatment programs significantly increased vaccine compl...
A study suggests that Ontario's current vaccination strategy for hepatitis B is inadequate, as many children are infected before receiving the vaccine. The authors recommend that all women be screened for HBV during pregnancy and that newborns receive the vaccine at birth.
Novel agents targeting viral production and immune response show promising results in early clinical trials. Four studies presented at DILC 2020 evaluated the strategy of disrupting viral protein synthesis using RNA interference and antisense oligonucleotides, with two combining NRTIs with novel therapies achieving significant HBsAg re...
Researchers at the University of Delaware used supercomputing resources to gain insights into the hepatitis B virus's genetic blueprint and how its protein shell assembles itself. They found that a mutation impairs this assembly process, revealing communication between different regions of the protein.
A significant number of people living with hepatitis B and C infections across Europe remain undiagnosed, hindering progress towards the Sustainable Development Goal for health. Effective testing strategies and linkage to care can help prevent transmission and improve health outcomes.
A retrospective cohort study in Sweden found ongoing transmission of hepatitis C before anti-HCV screening was implemented in 1992. The study identified undiagnosed hepatitis C patients living in Sweden who received transfusions pre-1992, emphasizing the need for testing and treatment.
Researchers at Helmholtz Zentrum München developed a novel therapeutic approach to cure chronic hepatitis B infection. By knocking down the expression of the virus' proteins, they enabled successful vaccination with TherVacB, a novel therapeutic vaccine. The therapy aims to cure existing chronic diseases by activating immune cells.
A team led by Professor Patrick Labonté identified the role of autophagy in the replication cycle of Hepatitis D virus, which infects only people with hepatitis B. The discovery could lead to a targeted treatment, but raises concerns about long-term effects on cellular function.
ApoE promotes hepatitis B virus infection and production, but targeting it with inhibitors may serve as an antiviral strategy for chronic HBV infection. Research found that apoE is enriched on the virus envelope and its expression impairs HBV production.
Researchers have identified an unusual hepatitis B virus in shrews, which lacks a key protein essential for chronic infection. This discovery offers new insights into the disease's pathogenesis and may lead to the development of effective treatments.
Viral hepatitis affects around 9 million Europeans, with over 50,000 newly diagnosed cases annually. Targeted testing is essential to reach those at risk and reduce undiagnosed infections.
The USPSTF has reaffirmed its 2009 recommendation to screen for hepatitis B virus (HBV) infection in pregnant women, identifying infants at risk of acquiring the infection from their mothers. Screening during pregnancy can prevent chronic HBV infection in children who become infected with HBV.
Since 2008, chronic hepatitis B infections have increased steadily in Europe, with 58% of newly reported cases classified as chronic in 2017. Successful national vaccination programmes have contributed to a decline in acute cases, but incomplete data and varying surveillance systems hinder detailed epidemiological analysis.
Researchers at Helmholtz Zentrum München have developed a novel T-cell therapy that can eliminate hepatitis B viruses from the liver, paving the way for a potential cure. The therapy involves genetically modifying patient-specific T cells to recognize and attack infected liver cells, with promising results in a mouse model.
Researchers at Nanjing University have developed a novel RNAi therapy using plant-derived silencing RNAs to inhibit HBsAg expression in mice, showing potential for affordable and effective treatment of chronic hepatitis B. The approach uses methylated short interfering sequences produced by plant endogenous microRNA biogenesis machiner...
Researchers have developed an orally administered hepatitis B vaccine that is both effective and safe. The new vaccine uses a technique called 3D imaging to understand how the vaccine behaves in the body, leading to improved efficacy and reduced side effects.
A study published in PLOS Pathogens reveals that hepatitis B viral protein HBeAg expands immune cells called MDSCs, impairing antiviral responses. The HBeAg-MDSC-IDO axis is a potential target for developing novel HBV therapeutics.
Scientists at the Institut Pasteur have identified a cellular protein that can degrade hepatitis B virus DNA, potentially leading to a 'Trojan horse' approach to target infected liver cells. This discovery offers new hope for developing curative treatments for chronic HBV infection.
Scientists found that current WHO guidelines for chronic hepatitis B fail to detect 50% of patients in need of treatment in Ethiopia. The guidelines are based on European and American data, highlighting the need for regionalized approaches to identify patients with significant liver disease.
Researchers used HBV genome sequences to infer ancient human migration into Australia, revealing unique viral strain and geographical connections. The study adds weight to the theory of mainland Aboriginal population separation at least 59 thousand years ago.
A study published in Vaccine found that introducing Hepatitis B vaccination in preadolescents led to a significant decline in the disease incidence rate from 2.5 per 100,000 people in 1991 to 1.2 per 100,000 people in 2014.
A large study of cancer patients reveals a significant proportion are undiagnosed with acute and chronic hepatitis B and C. The findings suggest that universal screening for these viruses may be warranted to prevent life-threatening complications and improve treatment outcomes.
Researchers found that hepatitis B virus (HBV)-associated acute liver failure results from an uncommon encounter between a highly mutated HBV variant and an unusual immune response in the patient's liver. By analyzing liver samples, they discovered new mechanisms about the disease, providing insights into its development.
The hepatitis B virus is highly stable at room temperature and can withstand temperatures of four degrees centigrade for nine months. Disinfectants are effective against the virus when applied undiluted, but their effectiveness decreases with dilution.
A new study found that genetic variation in Caucasians with chronic hepatitis B infection increases the risk of severe liver damage and inflammation. Researchers identified a link between the STAT4 gene and liver fibrosis, suggesting that genetic factors may play a role in disease progression.
Researchers developed an accurate diagnostic score that uses two simple blood tests to identify patients in need of treatment against the deadly hepatitis B virus. The test was found to be as accurate as existing methods but at a fraction of the cost, making it accessible for sub-Saharan Africa's poorest regions.
The study highlights the significant burden of hepatitis B virus globally, with 292 million individuals living with the virus in 2016. Only 5% of eligible patients received antiviral therapy, and less than 1% of expectant mothers with high viral load received prophylaxis to prevent mother-to-child transmission.
A phase III clinical trial in Thailand tested TDF therapy against standard preventative measures, finding no significant reduction in infant infection rates. The study suggests that adding TDF may have little effect on mother-to-child transmission rates already at low levels.
Recent studies investigate the role of cholesterol and other lipids in blood circulation, discovering a correlation between bad cholesterol levels and muscle damage in muscular dystrophy patients. Another study reveals a synergistic effect of hepatitis B and alcohol on cholesterol metabolism, increasing biosynthesis and impairing uptake.
New virus-cracking molecules can disrupt viral capsid assembly, preventing replication and killing new copies of the virus. This breakthrough could lead to better treatments against multiple viruses, including polio and herpes.
A public health-primary care collaboration tested individuals aged 40-70 in two Dutch hotspots, achieving high test uptake of 51% without detecting active/chronic hepatitis C. The strategy may be effective in areas with high disease rates but not recommended for low prevalence countries.
The American College of Physicians (ACP) and the Centers for Disease Control and Prevention (CDC) advise physicians to vaccinate all unvaccinated adults against hepatitis B virus (HBV) infection and screen high-risk persons. This can help reduce chronic HBV infections, cirrhosis, hepatocellular carcinoma, and premature death.
The American College of Physicians and Centers for Disease Control and Prevention recommend screening at-risk adults, increasing hepatitis B vaccination rates, and linking infected persons to care. This can help reduce transmission and complications associated with chronic hepatitis B infection.
Researchers at Texas Biomedical Research Institute tested a new drug for hepatitis B virus infection, which uses RNA interference to reduce surface antigens. The therapy has shown safety and effectiveness in human trials, offering hope for a potential cure.
New data reveals 52 million children globally affected by viral hepatitis, highlighting the need for treatment and prevention. Despite declining hepatitis B infections among children, cases of hepatitis C are expected to continue growing due to lack of programs for pregnant women living with the virus.
Australia is currently on track to eliminate hepatitis C due to its efforts in enabling population-wide access to treatment. However, maintaining high annual treatment numbers is crucial to meet the 2030 elimination target. For hepatitis B, progress is slower, and a significant commitment is needed to achieve the elimination goals.
Chronic hepatitis B and C cause life-threatening liver damage, cancer, and premature death, with 300 million infected worldwide. Donors are essential to deliver results in the next 13 years, as domestic funding is unlikely to meet the challenge.
Nine countries are making progress towards eliminating hepatitis C, thanks to innovative approaches and increased funding. Brazil, Egypt, Australia, and Georgia are leading the way with mass screenings, vaccination campaigns, and risk-sharing agreements.